HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Suggests NIH Office Of Dietary Supplements Get More Current, Collaborative

Executive Summary

Industry comments on NIH ODS strategic plan focus on persuading it to give trade associations input on its activities, specifically for fact sheets on dietary supplement topics. Stakeholders also want more dialogue with ODS and opportunity to comment on initiatives.

You may also be interested in...



CHPA Urges NIH Office of Dietary Supplements To ‘Educate’ Congress, FDA On Label Database

With Congress considering mandatory supplement product listing as requested by FDA, trade group asks NIH’s Office of Dietary Supplements to share its experience building and maintaining its label database.

Vitamin D Supplements And COVID-19: Still No Evidence, No Harm In Doing It Anyway

Two new RCTs cast further doubt on the preventative effects of vitamin D supplementation with regards to COVID-19 infection. Nevertheless, an editorial in the British Medical Journal, where the studies were published, leaves open positive effects for those suffering from vitamin D deficiency, and recommends a daily supplement of up to 2000IU just in case.

HBW Market News: CHPA CFO Awarded, Olive Natural Packaging, ODS Plan, IFF South America

CHAP’s Brian Green is Association TRENDS 2022 Association CFO of the Year; “Matisse-like dreamscape” In Olive Natural Packaging redesign; NIH’s ODS wants strategic plan input; and IFF innovation centers in Brazil, Chile, Colombia.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel